Home
overview
Arthritis is the leading causes of disability and with the ageing population of the developed world the market for arthritis drugs in set to significantly increase over the next 5-10 years, reaching an estimated $21bn by 2010.

With the large number of DMARDS set to enter the market over the next couple of years there is impatience for increasingly effective, safe anti-arthritic drugs that act to arrest the progression of the disease or even reverse bone and cartilage damage.

This Conference will aim to stimulate discussion between key academic opinion leaders and experts from the pharmaceutical and biotech industries on issues surrounding strategic trial design and provide an update on drugs in development from the market leaders for both RA and OA. The event intends to look at the latest regulatory guidelines and how to submit information to the authorities, how to overcome the challenges of selecting effective endpoints and appropriate comparator drugs and developments in tools for assessing disease progression. The programme will discuss the use of drugs in combination and how side-effects can be reduced to address safety concerns associated with many anti-arthritic agents to date.

A unique opportunity to learn from leading industry experts including:

  • Dr Ketan Desai, Vice President, Preclinical & Clinical Research, Neose Technologies (formerly at Aventis)
  • Dr Anthony Manning, Vice President, Arthritis Research, Roche
  • Prof Gabriel Panayi, ARC Professor, Rheumatology, King's College London
  • Dr Philip Simon, Executive Director, Arthritis & Bone Metabolism, Novartis
  • Dr David Stirling, Chief Scientific Officer & Executive Vice President, Pharmaceutical R&D, Celgene
  • Dr Stephen Myers, Senior Clinical Research Physician, Inflammation/Immunomodulation, Eli Lilly
  • Prof David Scott, Professor, Rheumatology, King's College Hospital
  • Dr Nell Moore, Director, Biology, AstraZeneca
  • Dr Neil Gozzard, Head, Pharmacology, Celltech
  • Dr Wolfgang Albrecht, Head, Drug Research, Merckle


  • Conference programme

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Dr Klaus Noever

    Dr Klaus Noever, Director, Business Development & Clinical Affairs, Europe, Bio-Imaging Technologies
    View Bio

    9:10 MARKET OPPORTUNITIES FOR RHEUMATOID ARTHRITIS DRUGS

    Melissa Garland

    Melissa Garland, Research Analyst, Decision Resources

  • Current treatment approaches: trends to watch
  • Unmet needs: tapping opportunity
  • Emerging therapies: pipeline hot list
  • Market outlook: United States, Europe, Japan
  • Future commercial opportunities
  • 9:40 TRIAL DESIGN AND THE PATIENT

    Prof David Scott

    Prof David Scott, Professor, Rheumatology, King’s College Hospital

  • Trends in patient epidemiology
  • Meeting the needs of the patient
  • 10:20 CHOICE OF EFFECTIVE ENDPOINTS IN RHEUMATOID ARTHRITIS

    Dr Stephen Myers

    Dr Stephen Myers, , Senior Clinical Research Physician, Inflammation/Immunomodulation, Eli Lilly

  • The ACR response elements
  • Pain and global assessment scales
  • Who is an ACR responder?
  • Pros and cons of the DAS endpoints
  • Multiple-endpoint testing
  • 11:00 Morning Coffee

    11:20 PANEL DISCUSSION:

    Dr Ketan Desai

    Dr Ketan Desai, Vice President, Preclinical & Clinical Research, ANeose Technologies (formerly at Aventis)

    Tim Shaw

    Tim Shaw, Clinical Science Leader, Roche Products

    Dr Ernest Choy

    Dr Ernest Choy, Consultant Rheumatologist & Director of the Sir Alfred Baring Garrod Clinical Trials Unit, Kings College London

    12:00 A NEW DIAGNOSTIC MARKER FOR RHEUMATOID ARTHRITIS

    Dr Anil Vasishta

    Dr Anil Vasishta, Divisional Director, Axis-Shield

  • Anti-citrullinated protein antibodies
  • Anti-CCP - a highly specific marker for RA
  • Anti-CCP antibodies are present very early in the disease
  • Predicting disease outcome
  • Role in the pathophysiology of RA
  • 12:40 Networking Lunch

    14:00 NOVEL ANTI-ARTHRITIC AGENTS

    Dr David Stirling

    Dr David Stirling, Chief Scientific Officer & Executive Vice President, Pharmaceutical Research & Development, Celgene

  • Immune modulating drugs
  • Phosphodiesterase 4 drugs
  • Kinase inhibitors
  • Preclinical studies
  • Clinical status
  • 14:40 EMERGING ORAL THERAPIES FOR RHEUMATOID ARTHRITIS

    Dr Neil Gozzard

    Dr Neil Gozzard, Head, Pharmacology, Celltech

  • Discovery, potency and selectivity
  • Drug disposition
  • Efficacy in primary and disease models in vivo
  • Safety and toxicology
  • Phase I clinical data
  • 15:20 NOVEL APPROACHES

    Dr Nell Moore

    Dr Nell Moore, Director, Biology, AstraZeneca

  • Which mechanism should we choose?
  • Preclinical progress
  • Clinical progress
  • What does the future hold?
  • 16:00 Afternoon Tea

    16:20 IL-6 IN AUTO-IMMUNE DISEASES

    Dr Anthony Manning

    Dr Anthony Manning, Vice President, Arthritis Research, Roche

  • IL-6 is a pleiotropic cytokine regulating immune responses and acute phase reactions
  • Deregulation of IL-6 has been implicated in the pathogenesis of a variety of diseases
  • The functions of IL-6 are mediated through a receptor system comprising a signal transducer and a binding molecule (the IL-6 receptor)
  • Blockade of IL-6 binding to its receptor using a novel monoclonal antibody has demonstrated clinical efficacy in heumatoid arthritis and several other IL-6 dependent diseases
  • This presentation will review this topic and emerging data on the potential of this therapeutic strategy in auto-immune disease
  • 17:00 TARGETING B CELLS IN THE TREATMENT OF RA

    Tim Shaw

    Tim Shaw, Clinical Science Leader, Roche Products

  • Understand the potential role of B cells in the pathogensis of RA
  • Rituximab as a targeted B cell therapy
  • What we already know about rituximab from the treatment of non-Hodgkins lymphoma
  • Review of the current clinical data on rituximab in RA
  • 17:40 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration & Coffee

    9:00 Chairman's Opening Remarks

    Prof David Scott

    Prof David Scott, Professor, Rheumatology, King’s College Hospital

    9:10 COMBINATION THERAPIES IN THE TREATMENT OF ARTHRITIS

    Dr Ketan Desai

    Dr Ketan Desai, Vice President, Preclinical & Clinical Research, ANeose Technologies (formerly at Aventis)

  • New data on traditional combinations
    • Methotrexate and Sulphasalazine
    • Methotrexate and Cyclosporine
  • New combinations
    • Methotrexate and Leflunomide
    • Methotrexate and Etanercept
    • Methotrexate and Infliximab
  • Potential new combinations
  • 9:40 ADVANCES IN THE TREATMENT OF OA

    Dr Wolfgang Albrecht

    Dr Wolfgang Albrecht, Head, Drug Research, Merckle

  • OA – pathology, risk factors, biomarkers
  • Role of cytokines and eicosanois in OA
  • Molecular targets for treatment of OA
  • Promises and limitations of Disease-Modifying Osteoarthritis Drugs (DMOADs)
  • An update on the LOX/COX inhibitor Licofelone
  • 11:00 Morning Coffee

    11:20 BIP: A NEW IMMUNOMODULATOR WITH ANTI-ARTHRITIC PROPERTIES

    Prof Gabriel Panayi

    Prof Gabriel Panayi, ARC Professor, Rheumatology, King’s College London

  • BiP is an endoplasmic reticulum chaperone
  • As an intra-cellular chaperone it protects cells from stress
  • We have found that it is present extra-cellularly in body fluids
  • As an extra-cellular protein it stimulates IL-10 production from monocytes
  • It both prevents and treats collagen induced arthritis in the mouse
  • 12:00 MEMBRANE-LOCALISING BIOPHARMACEUTICALS IN ARTHRITIS

    Dr Richard Smith

    Dr Richard Smith, Chief Scientific Officer, AdproTech

  • Back to the membrane – why and how?
  • The complement system in rheumatoid arthritis – relationship to cellular responses
  • A new generation of therapeutics
  • Preclinical evaluation of MIrococept
  • Clinical studies
  • 12:40 Networking Lunch

    14:00 MONOCLONAL ANTIBODY AGAINST VEGF RECEPTOR-1: A POTENTIAL NEW APPROACH TO TREAT INFLAMMATORY DISEASES

    Dr Peter Bohlen

    Dr Peter Bohlen, Senior Vice President, Research, ImClone Systems

  • Fully human monoclonal antibody designed to block ligand-induced activation of VEGFR1
  • VEGFR1 mab inhibits disease progression in mouse models of arthritis and atherosclerosis
  • Although VEGFR1 is thought to be involved in angiogenesis, the major mechanism of action of VEGFR1 mab is independent of endothelial cell function in these models
  • VEGFR1 mab inhibits influx of inflammatory cells to sites of inflammation. The mechanism of this action is thought to be the inhibition of recruitment from bone marrow of hematopoietic precursor and inflammatory cells
  • 14:40 CHEMOKINE RECEPTORS AND SMALL MOLECULES

    Dr William Hipkin

    Dr William Hipkin, Senior Principal Scientist, Schering-Plough

  • What's out there?
  • The receptor has two states
  • Working with chemokine receptors: CCR2, CXCR2, CXCR3, CCR5
  • 14:40 SELECTIVE ADHESION MOLECULE INHIBITOR THERAPY FOR RHEUMATOID ARTHRITIS

    Dr Theresa Podrebarac

    Dr Theresa Podrebarac, Associate Medical Director, Biogen Idec

  • Review alpha 4 integrin biology, expression and function
  • Summarise preclinical data supporting the technical rationale of alpha 4
  • Blockade in autoimmunity
  • Present phase II data from Crohns disease and MS to support alpha 4 targetting
  • 17:00 Chairman's Closing Remarks Followed by Afternoon Tea and Close of Conference

    +

    Workshops

    Imaging in Arthritis
    Workshop

    Imaging in Arthritis

    The Hatton, at etc. venues
    28th April 2004
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.